UNITY BIOTECHNOLOGY INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
UNITY BIOTECHNOLOGY INC. - More news...
UNITY BIOTECHNOLOGY INC. - More news...
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
- UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
- UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
- UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
- UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
- UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
- UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
- UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye
- UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration
- UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
- UNITY Biotechnology Announces Proposed Public Offering of Common Stock
- UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
- UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
- UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
- UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology Announces Appointment of Accomplished Finance and Operations Executive Michael Samar to the Board of Directors
- UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
- UNITY Biotechnology, Inc. Reports First Quarter 2022 Financial Results and Business Updates
- UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degeneration
- UNITY Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema
- UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
- UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
- UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology Provides Program Updates and Anticipated Milestones for 2022
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program
